Brief: Trevi Therapeutics Announces Positive Topline Results From Its Phase 2a RIVER Trial Of Haduvio For Treatment Of Patients With RCC
10/03/2025 10:06
March 10 (Reuters) - Trevi Therapeutics Inc TRVI.O: TREVI THERAPEUTICS INC: HADUVIO MET PRIMARY ENDPOINT TREVI THERAPEUTICS: ANNOUNCE POSITIVE TOPLINE RESULTS FROM ITS PHASE 2A RIVER TRIAL OF HADUVIO FOR TREATMENT OF PATIENTS WITH RCC (N=66) TREVI THERAPEUTICS: PATIENT REPORTED & OTHER SECONDARY OUTCOMES WERE STATISTICALLY SIGNIFICANT & CONSISTENT WITH PRIMARY ENDPOINT Source text: ID:nPn7xKPQHa Further company coverage: TRVI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million